Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : View from the Center and Left -- Ignore unavailable to you. Want to Upgrade?

To: neolib who wrote (229249)	8/13/2013 8:33:42 PM
From: Bread Upon The Water	Read Replies (2) \| Respond to of 542132

As a counterforce to technology reducing admin costs it is also a factor, IMHO, in driving up medical costs as we discover new and technically dependent ways to treat people. this especially true in the emerging field of drugs targeting pathologies either based on their DNA make up or acting in response to chemical proteins within the pathogenic cell. So it all might just be a wash if we're that lucky. Eg. New targeted drug treatment for lung cancer costs 10,000 a shot. The new drug for prostate cancer, Provenge, bills out at 100,000 for a six week treatment (although insurers get discounts).